PC
CLVS

PointState Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

PointState Capital’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-193,712
Closed -$4.81M – 162
2019
Q1 		$4.81M Sell
193,712
-743,964
-79% -$18.7M 0.09% 74
2018
Q4 		$16.8M Sell
937,676
-2,005,228
-68% -$41M 0.67% 29
2018
Q3 		$86.4M Sell
2,942,904
-102,906
-3% -$3.98M 1.14% 29
2018
Q2 		$138M Buy
3,045,810
+503,687
+20% +$24.5M 1.57% 21
2018
Q1 		$134M Sell
2,542,123
-364,726
-13% -$21.3M 1.46% 23
2017
Q4 		$198M Buy
2,906,849
+540,400
+23% +$37.8M 1.92% 20
2017
Q3 		$195M Buy
2,366,449
+371,310
+19% +$29.4M 1.66% 18
2017
Q2 		$187M Sell
1,995,139
-30,906
-2% -$1.89M 2.03% 18
2017
Q1 		$129M Sell
2,026,045
-1,145,933
-36% -$69.7M 1.35% 23
2016
Q4 		$141M Buy
3,171,978
+367,214
+13% +$12.9M 2.03% 12
2016
Q3 		$101M Buy
2,804,764
+576,240
+26% +$12.4M 1.04% 27
2016
Q2 		$30.6M Sell
2,228,524
-1,367,656
-38% -$20M 0.63% 34
2016
Q1 		$69M Buy
3,596,180
+92,280
+3% +$1.95M 1.86% 15
2015
Q4 		$123M Buy
3,503,900
+3,453,900
+6,908% +$223M 3.12% 9
2015
Q3 		$4.6M Sell
50,000
-205,000
-80% -$17.7M 0.13% 64
2015
Q2 		$22.4M Buy
255,000
+55,000
+28% +$4.71M 0.26% 65
2015
Q1 		$14.8M Buy
+200,000
New +$14.1M 0.2% 72
2014
Q3 		– Sell
-50,000
Closed -$2.07M – 145
2014
Q2 		$2.07M Sell
50,000
-80,000
-62% -$4.12M 0.03% 115
2014
Q1 		$9.01M Buy
130,000
+55,000
+73% +$4.04M 0.14% 75
2013
Q4 		$4.52M Buy
75,000
+10,000
+15% +$544K 0.06% 118
2013
Q3 		$3.95M Buy
+65,000
New +$4.61M 0.07% 111

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

PointState Capital's CLVS Position: Q2 2019 in Review

PointState Capital sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 193,712 shares — an estimated $4.81M sold.

PointState Capital first reported a position in CLVS in Q3 2013 and held it in 21 quarters. The position peaked at $198M in Q4 2017. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

  • PointState Capital reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
  • PointState Capital sold 193,712 Clovis Oncology, Inc. shares in Q2 2019, an estimated $4.81M.
  • PointState Capital first reported a position in Clovis Oncology, Inc. in Q3 2013 and held it in 21 quarters.
  • PointState Capital's Clovis Oncology, Inc. position peaked at $198M in Q4 2017.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on PointState Capital's 13F filing for Q2 2019, filed 14 Aug 2019.